Rare Tumours programme
Coordinator: Paolo Casali, Milan, IT
ESO joins the worldwide movement about rare cancers. ESO is already covering pediatric cancers (all of which are rare) and haematological cancers (many of which are rare) and has now decided to set up a specific programme on rare solid cancers of the adult. There is a huge educational gap on these tumors, which ESO will help fill.
According to the RARECARE project, rare solid cancers of the adult make up 15% of all new cancer cases, being the following:
|1. || || ||Sarcomas |
| 2.|| || ||Rare thoracic tumors (mesothelioma, thymic neoplasms) |
| 3.|| || ||Neuroendocrine tumors |
| 4.|| || ||Endocrine gland tumors |
| 5.|| || ||Head & neck cancers |
| 6.|| || ||Central nervous system neoplasms |
| 7.|| || ||Digestive rare cancers |
| 8.|| || ||Rare urological and male genital tumors |
| 9.|| || ||Rare female genital cancers |
| 10.|| || ||Rare skin cancers & non-cutaneous melanoma|
There is a growing demand for medical education of young oncologists willing to devote their professional life to some or all rare adult solid cancers. So, ESO will collaborate with the upcoming international post-graduate Master on Oncology of Rare Adult Solid Cancers of the University of Milan, Italy.
In partnership with ESMO, every year ESO will organize an annual Advanced Course, Clinical Update on Rare Adult Solid Cancers, as a regular appointment for clinical oncologists and to keep them updated on novelties about rare adult solid cancers.
ESO is aware that medical education should tackle rarity appropriately. Standard medical education is unlikely to succeed when trainees do not regularly encounter the disease in their everyday practice. This is the reason why educational efforts on rare cancers should be preferably shaped with a view to the healthcare facilities in the community, especially looking at existing networks. In fact, networking is the keyword to improve quality of care of rare cancers. In the end, educational efforts should try to be instrumental to existing healthcare networks covering rare cancers. Thus, ESO joined the upcoming Joint Action on Rare Cancers of the European Union, a project coordinated by the Istituto Nazionale Tumori, Milan, Italy, with which ESO has developed all these initiatives. This Joint Action looks forward to the creation of the new European Reference Networks (ERNs) on rare cancers, following the Cross-border Healthcare Directive of the EU.
ESO is actively involved in the European rare cancer community with a seat in the Steering committee of Rare Cancers Europe (RCE), the multi-stakeholder effort launched by ESMO in partnership with clinical and research communities, patient groups, industries, as a “think-tank” to tackle the several issues posed by rare cancers.
For further information regarding these programme please contact:
Rare Tumours Programme